AYAda Wing Chi Yan

Ada Wing Chi Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ada Wing Chi Yan has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modelling Between-Cell-Type Heterogeneity in Within-Host Influenza Virus Infection

    by Ada W. C. Yan, Steven Riley, James M. McCaw

    Cell tropism, or the preference of a virus for particular cell types, has major implications for viral transmission, pathogenesis, and evolution. Historically, changes in cell tropism for particular viruses have been observed to correlate to changes in viral fitness, in the form of increased within-host replication and increased transmission between hosts. This is illustrated in the context of influenza, where adaptation to infect cells expressing $$\alpha $$ α 2-6 linked sialic acid receptors enhances human-to-human transmissibility. Target cell populations differ not only in abundance but also in intrinsic properties such as susceptibility, viral production, and interferon responses, rendering the relationship between tropism and viral fitness multi-faceted and complex. Understanding how different cell tropisms quantitatively change fitness remains an important open question in virology and quantitative biology. Here, we present a within-host mathematical model that incorporates distinct target cell types differing in key properties, and examine how cell tropism affects fitness-related summary statistics such as peak viral load, infection duration, or total virus produced. Our analysis reveals that tradeoffs may arise when cell types differ by multiple characteristics. We further demonstrate that model parameters describing heterogeneity between cell types can be more accurately inferred when cell type proportions are measured alongside viral load. Our findings provide a framework for assessing the links between viral evolution, cell tropism, and within-host fitness, and motivate the design of experiments to collect quantitative data on between-cell-type heterogeneity.

  • Open Access

    Modelling between-cell heterogeneity in within-host influenza virus infection

    by Ada W. C. Yan, Steven Riley, James M. McCaw

    Cell tropism, or the preference of a virus for particular cell types, has major implications for viral transmission, pathogenesis, and evolution. An increase in viral fitness --- increased within-host replication, also leading to increased transmission between hosts --- can result from a virus changing its cell tropism. This is illustrated in the context of influenza, where adaptation to infect cells expressing $\alpha$2-6 linked sialic acid receptors enhances human-to-human transmissibility. Target cell populations differ not only in abundance but also in intrinsic properties such as susceptibility, viral production, and interferon responses, rendering the relationship between tropism and viral fitness multi-faceted and complex. Understanding how different cell tropisms quantitatively change fitness remains an important open question in virology and quantitative biology. Here, we present a within-host mathematical model that incorporates distinct target cell types differing in key properties, and examine how cell tropism affects viral fitness, as measured by metrics such as peak viral load, infection duration, or total virus produced. Our analysis reveals that tradeoffs may arise when cell types differ by multiple characteristics. We further demonstrate that model parameters describing heterogeneity between cell types can be more accurately inferred when cell type proportions are measured alongside viral load. Our findings provide a framework for assessing the links between viral evolution, cell tropism, and within-host fitness, and motivate the design of experiments to collect quantitative data on between-cell heterogeneity.

  • Open Access

    The impact of model assumptions in interpreting cell kinetic studies

    by Ada Wing Chi Yan, Ildar Sadreev, Jonas Mackerodt, Yan Zhang, Derek Macallan, Robert Busch, Becca Asquith

    Stable isotope labelling is one of the best methods currently available for quantifying cell dynamics in vivo, particularly in humans where the absence of toxicity makes it preferable over other techniques such as CFSE or BrdU. Interpretation of stable isotope labelling data (as for BrdU and CFSE) necessitates simplifying assumptions. Here we investigate the impact of three of the most commonly used simplifying assumptions: (i) that the cell population of interest is closed, (ii) that the population of interest is kinetically homogeneous, and (iii) that the population is spatially homogeneous and suggest pragmatic ways in which the resulting errors can be reduced.


  • Open Access

    Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types

    by Clare P. McCormack, Ada W. C. Yan, Jonathan C. Brown, Ksenia Sukhova, Thomas P. Peacock, Wendy S. Barclay, Ilaria Dorigatti

    We use viral kinetic models fitted to viral load data from in vitro studies to explain why the SARS-CoV-2 Omicron variant replicates faster than the Delta variant in nasal cells, but slower than Delta in lung cells, which could explain Omicron's higher transmission potential and lower severity. We find that in both nasal and lung cells, viral infectivity is higher for Omicron but the virus production rate is higher for Delta, with an estimated approximately 200-fold increase in infectivity and 100-fold decrease in virus production when comparing Omicron with Delta in nasal cells. However, the differences are unequal between cell types, and ultimately lead to the basic reproduction number and growth rate being higher for Omicron in nasal cells, and higher for Delta in lung cells. In nasal cells, Omicron alone can enter via a TMPRSS2-independent pathway, but it is primarily increased efficiency of TMPRSS2-dependent entry which accounts for Omicron's increased activity. This work paves the way for using within-host mathematical models to understand the transmission potential and severity of future variants.


  • Open Access

    KIR-HLA interactions extend human CD8+ T cell lifespan in vivo

    by Yan Zhang, Ada W.C. Yan, Lies Boelen, Linda Hadcocks, Arafa Salam, Daniel Padrosa Gispert, Loiza Spanos, Laura Mora Bitria, Neda Nemat-Gorgani, James A. Traherne, et al.

    BACKGROUND. There is increasing evidence, in transgenic mice and in vitro, that inhibitory killer cell immunoglobulin-like receptors (iKIRs) can modulate T cell responses. Furthermore, we have previously shown that iKIRs are an important determinant of T cell–mediated control of chronic viral infection and that these results are consistent with an increase in the CD8+ T cell lifespan due to iKIR-ligand interactions. Here, we tested this prediction and investigated whether iKIRs affect T cell lifespan in humans in vivo. METHODS. We used stable isotope labeling with deuterated water to quantify memory CD8+ T cell survival in healthy individuals and patients with chronic viral infections. RESULTS. We showed that an individual’s iKIR-ligand genotype was a significant determinant of CD8+ T cell lifespan: in individuals with 2 iKIR-ligand gene pairs, memory CD8+ T cells survived, on average, for 125 days; in individuals with 4 iKIR-ligand gene pairs, the memory CD8+ T cell lifespan doubled to 250 days. Additionally, we showed that this survival advantage was independent of iKIR expression by the T cell of interest and, further, that the iKIR-ligand genotype altered the CD8+ and CD4+ T cell immune aging phenotype. CONCLUSIONS. Together, these data reveal an unexpectedly large effect of iKIR genotype on T cell survival. FUNDING. Wellcome Trust; Medical Research Council; EU Horizon 2020; EU FP7; Leukemia and Lymphoma Research; National Institute of Health Research (NIHR) Imperial Biomedical Research Centre; Imperial College Research Fellowship; National Institutes of Health; Jefferiss Trust.


  • Open Access

    Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types

    by Clare P. McCormack, Ada W. C. Yan, Jonathan C. Brown, Ksenia Sukhova, Thomas P. Peacock, Wendy S. Barclay, Ilaria Dorigatti

    We use viral kinetic models fitted to viral load data from in vitro studies to explain why the SARS-CoV-2 Omicron variant replicates faster than the Delta variant in nasal cells, but slower than Delta in lung cells, which could explain Omicron’s higher transmission potential and lower severity. We find that in both nasal and lung cells, viral infectivity is higher for Omicron but the virus production rate is higher for Delta. However, the differences are unequal between cell types, and ultimately leads to the basic reproduction number and growth rate being higher for Omicron in nasal cells, and higher for Delta in lung cells. In nasal cells, Omicron alone can enter via a TMPRSS2-independent pathway, but it is primarily increased efficiency of TMPRSS2-dependent entry which accounts for Omicron’s increased activity. This work paves the way for using within-host mathematical models to understand the transmission potential and severity of future variants.


  • Top Cited Papers
    Open Access

    The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein

    by Thomas P. Peacock, Jonathan C. Brown, Jie Zhou, Nazia Thakur, Ksenia Sukhova, Joseph Newman, Ruthiran Kugathasan, Ada W.C. Yan, Wilhelm Furnon, Giuditta De Lorenzo, et al.

    The SARS-CoV-2 Omicron/BA.1 lineage emerged in late 2021 and rapidly displaced the Delta variant before being overtaken itself globally by, the Omicron/BA.2 lineage in early 2022. Here, we describe how Omicron BA.1 and BA.2 show a lower severity phenotype in a hamster model of pathogenicity which maps specifically to the spike gene. We further show that Omicron is attenuated in a lung cell line but replicates more rapidly, albeit to lower peak titres, in human primary nasal cells. This replication phenotype also maps to the spike gene. Omicron spike (including the emerging Omicron lineage BA.4) shows attenuated fusogenicity and a preference for cell entry via the endosomal route. We map the altered Omicron spike entry route and partially map the lower fusogenicity to the S2 domain, particularly the substitution N969K. Finally, we show that pseudovirus with Omicron spike, engineered in the S2 domain to confer a more Delta-like cell entry route retains the antigenic properties of Omicron. This shows a distinct separation between the genetic determinants of these two key Omicron phenotypes, raising the concerning possibility that future variants with large antigenic distance from currently circulating and vaccine strains will not necessarily display the lower intrinsic severity seen during Omicron infection.


  • Open Access

    Favipiravir-resistant influenza A virus shows potential for transmission

    by Daniel H. Goldhill, Ada Yan, Rebecca Frise, Jie Zhou, Jennifer Shelley, Ana Gallego Cortés, Shahjahan Miah, Omolola Akinbami, Monica Galiano, Maria Zambon, et al.

    Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity. However, the clinical relevance of these mutations is unclear as the mutations have not been found in natural isolates and it is unknown whether viruses harbouring these mutations would replicate or transmit in vivo. Here, we infected ferrets with a mix of wild type p(H1N1) 2009 and corresponding favipiravir-resistant virus and tested for replication and transmission in the absence of drug. Favipiravir-resistant virus successfully infected ferrets and was transmitted by both contact transmission and respiratory droplet routes. However, sequencing revealed the mutation that conferred resistance, K229R, decreased in frequency over time within ferrets. Modelling revealed that due to a fitness advantage for the PA P653L mutant, reassortment with the wild-type virus to gain wild-type PB1 segment in vivo resulted in the loss of the PB1 resistance mutation K229R. We demonstrated that this fitness advantage of PA P653L in the background of our starting virus A/England/195/2009 was due to a maladapted PA in first wave isolates from the 2009 pandemic. We show there is no fitness advantage of P653L in more recent pH1N1 influenza A viruses. Therefore, whilst favipiravir-resistant virus can transmit in vivo, the likelihood that the resistance mutation is retained in the absence of drug pressure may vary depending on the genetic background of the starting viral strain.


  • Open Access

    Favipiravir-resistant influenza A virus shows potential for transmission

    by Daniel H. Goldhill, Ada Yan, Rebecca Frise, Jie Zhou, Jennifer Shelley, Ana Gallego Cortés, Shahjahan Miah, Omolola Akinbami, Monica Galiano, Maria Zambon, et al.

    Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity. However, the clinical relevance of these mutations is unclear as the mutations have not been found in natural isolates and it is unknown whether viruses harbouring these mutations would replicate or transmit in vivo. Here, we infected ferrets with a mix of wild type p(H1N1) 2009 and corresponding favipiravir-resistant virus and tested for replication and transmission in the absence of drug. Favipiravir-resistant virus successfully infected ferrets and was transmitted by both contact transmission and respiratory droplet routes. However, sequencing revealed the mutation that conferred resistance, K229R, decreased in frequency over time within ferrets. Modelling revealed that due to a fitness advantage for the PA P653L mutant, reassortment with the wild-type virus to gain wild-type PB1 segment in vivo resulted in the loss of the PB1 resistance mutation K229R. We demonstrated that this fitness advantage of PA P653L in the background of our starting virus A/England/195/2009 was due to a maladapted PA in first wave isolates from the 2009 pandemic. We show there is no fitness advantage of P653L in more recent pH1N1 influenza A viruses. Therefore, whilst favipiravir-resistant virus can transmit in vivo, the likelihood that the resistance mutation is retained in the absence of drug pressure may vary depending on the genetic background of the starting viral strain. Author Summary: In the event of a new influenza pandemic, drugs will be our first line of defence against the virus. However, drug resistance has proven to be particularly problematic to drugs against influenza. Favipiravir is a novel drug which might be used against influenza virus in the event of a new pandemic. Is resistance likely to be a problem for the use of favipiravir? Our previous work has shown that resistance to favipiravir can be generated in cell culture but we don’t know whether there will be a cost preventing the spread of resistance in whole organisms. Here, we used a mix of wild-type and resistant influenza viruses from early in the 2009 pandemic to test whether viruses resistant to favipiravir could transmit between ferrets. We found that the resistant viruses could transmit but that the resistance mutation was selected against within some ferrets. Using modelling and in vitro experiments, we found that the resistant mutation was selected against in the influenza strain from our experiment but not in more recently evolved strains. Our results show that favipiravir resistant viruses could spread if resistance is generated but the probability will depend on the genetic background of the virus.

  • Open Access

    Saturation of influenza virus neutralization and antibody consumption can both lead to bistable growth kinetics

    by Shilian Xu, Ada W. C. Yan, Heidi Peck, Leah Gillespie, Ian G. Barr, Xiaoyun Yang, Stephen J. Turner, Celeste M Donato, Tonghua Zhang, Moshe Olshansky, et al.

    Influenza virus is a major human health threat. Neutralizing antibodies elicited through prior infection or vaccination play an irreplaceable role in protection from subsequent infection. The efficacy of antibody-dependent vaccines relies on both virus replication and neutralization, but their quantitative relationship was unknown. Here we use mathematical models to quantitatively investigate viral survivability determined by antibody concentration and inocula size. We performed focus reduction assays for 49 seasonal influenza A/H3N2 viruses circulating during 2017–2019 against influenza antisera raised in ferrets, and find that the antibody consumption rates of individual reactions were either small or large, and this was strongly positively correlated with virus saturation. Regardless of antibody consumption rate, virus-antibody interactions always lead to antibody-induced bistable viral kinetics. As a result, at a specific interval of antibody concentration, small viral inocula are eliminated but not large virus inocula, which is triggered by saturated virus neutralization or antibody consumption. Our finding highlights virus-antibody interaction with different antigenic properties, thereby explaining commonly observed influenza re-infection and enhancing vaccine efficiency.